Goniothalamin
(GTN), a natural compound isolated from Goniothalamus species, has previously demonstrated cytotoxic activity against
several cancer cell lines. However, similarly to many natural and
synthetic anticancer compounds, GTN presents toxicity toward some
healthy cells and low aqueous solubility, decreasing its bioavailability
and precluding its application as an antineoplastic drug. In our efforts
to improve the pharmacokinetic behavior and selectivity of GTN against
cancer cells, we developed a polymeric nanosystem, in which rac-GTN was encapsulated in pH-responsive acetalated dextran
(Ac-Dex) nanoparticles (NPs) with high loadings of the bioactive compound.
Dynamic light scattering (DLS) analysis showed that the nanoparticles
obtained presented a narrow size distribution of around 100 nm in
diameter, whereas electron microscopy (EM) images showed nanoparticles
with a regular spherical morphology in agreement with the size range
obtained by DLS. Stability and release studies indicated that the
GTN@Ac-Dex NPs presented high stability under physiological conditions
(pH 7.4) and disassembled under slightly acidic conditions (pH 5.5),
releasing the rac-GTN in a sustained manner. In vitro assays showed that GTN@Ac-Dex NPs significantly
increased cytotoxicity and selectivity against cancer cells when compared
with the empty Ac-Dex NPs and the free rac-GNT. Cellular
uptake and morphology studies using MCF-7 cells demonstrated that
GTN@Ac-Dex NPs are rapidly internalized into the cancer cells, causing
cell death. In vivo investigation confirmed the efficient
release of rac-GTN from GTN@Ac-Dex NPs, resulting
in the delay of prostate cancer progression in transgenic adenocarcinoma
of the mouse prostate (TRAMP) model. Furthermore, liver histopathology
evaluation after treatment with GTN@Ac-Dex NPs showed no evidence
of toxicity. Therefore, the in vitro and in vivo findings suggest that the Ac-Dex NPs are a promising
nanosystem for the sustained delivery of rac-GTN
into tumors.